MS-2307

A 72-year-old patient on a cardiology ward has been admitted with worsening heart failure for the third time this year. On the advice of his cardiologist, he has tried various drug and dosage regimes, but his pulmonary hypertension seems to be resistant to treatment.

The medical team is considering starting a continuous intravenous infusion of epoprostenol, a naturally occurring prostaglandin I2, also known as prostacyclin or PGI2. How will this medication affect the formation of blood clots?